A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Categories (click each to see list of all clinical trials associated with that category): Thoracic (ONC)
Current Status: Open
Phase: III (Cancer Control)
Principal Investigator: Zhen, Weining
Contact Information:
Jamie Willms
+1 402-559-8649
jamie.willms@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT04214262?term=NCT04214262&rank=1
Summary
PRIMARY OBJECTIVE:
I. To compare overall survival (OS) in patients with inoperable, early stage non-small cell lung cancer (NSCLC) randomized to stereotactic body radiation therapy (SBRT) with or without atezolizumab.
SECONDARY OBJECTIVES:
I. To compare investigator-assessed progression-free survival (IA-PFS) between the arms.
II. To compare progression free survival (PFS) by blinded independent centralized review (BIRC) between the arms in a random subset of patients.
III. To evaluate distant, locoregional, and local failure rates within each treatment arm.
IV. To evaluate the frequency and severity of toxicities within each treatment arm.
ADDITIONAL OBJECTIVE:
I. To collect specimens for banking.